Ocular Therapeutix
OCUL
OCUL
267 hedge funds and large institutions have $1.77B invested in Ocular Therapeutix in 2026 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 104 increasing their positions, 59 reducing their positions, and 51 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
4% more call options, than puts
Call options by funds: $22.1M | Put options by funds: $21.2M
24% less capital invested
Capital invested by funds: $2.33B → $1.77B (-$560M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Holders
267
Holding in Top 10
5
Calls
$22.1M
Puts
$21.2M
Top Buyers
| 1 | +$111M | |
| 2 | +$54.6M | |
| 3 | +$43.1M | |
| 4 |
VA
VR Adviser
New York
|
+$28.9M |
| 5 |
CC
Commodore Capital
New York
|
+$24.5M |
Top Sellers
| 1 | -$56.1M | |
| 2 | -$39.7M | |
| 3 | -$39M | |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$35.6M |
| 5 |
Millennium Management
New York
|
-$30.2M |
